Understanding how the PI3K pathway affects B cell tolerance in the immune system
Role and mechanisms of the PI3K pathway in B cell tolerance
This study looks at how the immune system tells the difference between good and bad B cells, which is important for preventing autoimmune diseases, and it could lead to new treatments for patients dealing with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10769737 on NIH RePORTER |
What this research studies
This research investigates the mechanisms that help the immune system distinguish between harmful and harmless B cells, focusing on the PI3K signaling pathway. By using specialized mouse models, the study examines how this pathway influences the development of B cells, particularly in preventing autoreactive B cells from causing autoimmune responses. The research aims to clarify how certain B cells are allowed to mature while others are eliminated, which is crucial for maintaining immune tolerance. Patients may benefit from insights gained into autoimmune diseases and potential new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with autoimmune conditions or those at risk of developing such conditions.
Not a fit: Patients with non-autoimmune related conditions or those without any B cell-related disorders may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating autoimmune diseases by enhancing our understanding of immune tolerance.
How similar studies have performed: Previous research has shown promising results in understanding B cell tolerance mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Pelanda, Roberta — University of Colorado Denver
- Study coordinator: Pelanda, Roberta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.